Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants accelerated approval for Otsuka’s IgAN therapy
Voyxact inhibits APRIL, a key factor in IgA nephropathy, reducing serum pathogenic Gd-IgA1 levels implicated in its development. Credit: sasirin pamai/Shutterstock.com.
Voyxact inhibits APRIL, a key factor in IgA nephropathy, reducing serum pathogenic Gd-IgA1 levels implicated in its development. Credit: sasirin pamai/Shutterstock.com.